GINKGO BIOWORKS HOLDINGS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M | $54.2M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $243.8M | $424.1M | $580.6M | $1.05B | $1.15B | $159.8M | $96.3M |
| SG&A Expense | $183.3M | $246.2M | $385.0M | $1.43B | $863.0M | $38.3M | $29.5M |
| Operating Income | $-315.3M | $-559.8M | $-864.4M | $-2.21B | $-1.83B | $-137.0M | $-71.6M |
| Operating Margin | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | -178.8% | -132.1% |
| Interest Expense | — | — | $93.0K | $106.0K | $2.4M | $2.4M | $2.4M |
| Pretax Income | $-313.6M | $-547.5M | $-892.9M | $-2.12B | $-1.84B | $-124.8M | $-119.8M |
| Income Tax Expense | $-837.0K | $-479.0K | $-71.0K | $-15.0M | $-1.5M | $1.9M | $22.0K |
| Net Income | $-312.8M | $-547.0M | $-892.9M | $-2.10B | $-1.83B | $-126.6M | $-119.3M |
| Net Margin | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | -220.2% |
| EPS (Basic) | $-5.64 | $-10.54 | $-18.37 | $-50.15 | $-1.35 | $-0.10 | $-0.10 |
| EPS (Diluted) | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-1.39 | $-0.10 | $-0.10 |
| Shares Outstanding (Basic) | 55.5M | 51.9M | 48.6M | 42.0M | 1.36B | 1.27B | 1.15B |
| Shares Outstanding (Diluted) | 55.5M | 51.9M | 48.6M | 42.0M | 1.36B | 1.27B | 1.15B |
| Dividends Per Share | — | — | — | — | — | — | — |